Valuation: Kidswell Bio Corporation

Market Cap 7.54B 48.07M 42.93M 39.66M 35.94M 67.24M 4.56B 68.35M 477M 189M 2.39B 180M 177M P/E 2027 *
7.72x
P/E 2028 * 5.03x
Enterprise Value 7.54B 48.07M 42.93M 39.66M 35.94M 67.24M 4.56B 68.35M 477M 189M 2.39B 180M 177M EV / Sales 2027 *
1.53x
EV / Sales 2028 * 1.34x
Free-Float
71.73%
Yield 2027 *
-
Yield 2028 * -
05-14 Kidswell Bio Corporation Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-14 Kidswell Bio Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-12 Kidswell Bio Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
11-13 Kidswell Bio Corporation Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 and Fiscal Year Ending March 31, 2027 CI
25-10-06 Alfresa Holdings Corporation Kidswell Bio Corporation. Chiome Bioscience Inc. and Mycenax Biotech Inc Announces Agreement in Principle to Establish Joint Venture for the Manufacturing of Drug Substance and Formulations of Biosimilars CI
25-08-13 Kidswell Bio Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 1, 2026 CI
25-01-13 Kidswell Bio Corporation announced that it has received ¥3.60111 million in funding from CVI Investments, Inc. CI
24-12-25 Kidswell Bio Corporation announced that it expects to receive ¥3.60111 million in funding from CVI Investments, Inc. CI
23-07-25 Kidswell Bio Corporation announced that it has received ¥22.8 million in funding from CVI Investments, Inc. CI
23-07-09 Kidswell Bio Corporation announced that it expects to receive ¥22.8 million in funding from CVI Investments, Inc. CI
22-09-19 Kidswell Bio Corporation(TSE:4584) dropped from S&P Global BMI Index CI
22-05-27 Japan Index Trims Gains over Inflationary Pressures; Dena to Take Majority Stake in Mobile ICT Business for $230 Million MT
22-05-27 Chiome Bioscience, Kidswell Bio to Collaborate on Development of Cancer Antibody MT
1 day-1.97%
1 week-5.10%
Current month-12.35%
1 month-8.59%
3 months+2.05%
6 months-37.66%
Current year-26.60%
1 week 146
Extreme 146
155
1 month 146
Extreme 146
171
Current year 125
Extreme 125
320
1 year 125
Extreme 125
320
3 years 88
Extreme 88
417
5 years 88
Extreme 88
540
10 years 88
Extreme 88
1,967.5
Manager TitleAgeSince
President 49 2023-05-31
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 78 2018-05-31
Director/Board Member 49 2023-05-31
Director/Board Member 62 2024-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-5.10%-41.11%+15.50% 48.07M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.05%+1.66%+40.44%+143.34% 38.32B
Weighted average by Cap. +0.39%+2.73%+47.56%+158.56%

Financials

2027 *2028 *
Net sales 4.92B 31.41M 28.05M 25.91M 23.48M 43.93M 2.98B 44.66M 312M 123M 1.56B 118M 115M 5.62B 35.81M 31.98M 29.54M 26.77M 50.08M 3.4B 50.91M 355M 141M 1.78B 134M 132M
Net income 753M 4.8M 4.29M 3.96M 3.59M 6.72M 456M 6.83M 47.67M 18.87M 239M 18.02M 17.64M 1.15B 7.36M 6.57M 6.07M 5.5M 10.29M 699M 10.46M 73.06M 28.92M 366M 27.62M 27.03M
Net Debt - -
Projected Income Statement - Annual - Kidswell Bio Corporation
Logo Kidswell Bio Corporation
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
Employees
32
Date Price Change Volume
26-10-23 JP¥149.00 -1.97% 316,600
26-10-22 JP¥152.00 -1.30% 241,600
26-10-21 JP¥154.00 +3.36% 227,200
26-10-20 JP¥149.00 -3.25% 264,500
26-10-19 JP¥154.00 -1.91% 199,500
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
149.00JPY
Average target price
450.00JPY
Spread / Average Target
+202.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kidswell Bio Corporation
  1. Stock Market
  2. Stocks
  3. 4584 Stock